Rezolute (RZLT) to Release Quarterly Earnings on Wednesday

Rezolute (NASDAQ:RZLT) is expected to issue its Q4 2026 results after the market closes on Wednesday, September 16th. Analysts expect the company to post earnings of ($0.1479) per share for the quarter. Parties can check the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Friday, September 25, 2026 at 4:00 PM ET.

Rezolute Price Performance

Shares of RZLT stock opened at $4.22 on Monday. Rezolute has a 12-month low of $1.07 and a 12-month high of $11.46. The company has a market capitalization of $406.34 million, a PE ratio of -5.15 and a beta of 0.60. The firm has a 50 day moving average price of $4.74 and a two-hundred day moving average price of $3.97.

Wall Street Analyst Weigh In

RZLT has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Friday, July 17th. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a report on Tuesday, June 30th. Maxim Group increased their price objective on Rezolute from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Citizens Jmp raised Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price for the company in a report on Wednesday, June 3rd. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Rezolute in a research report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.38.

Hedge Funds Weigh In On Rezolute

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. lifted its position in shares of Rezolute by 17.8% during the 4th quarter. Federated Hermes Inc. now owns 16,534,712 shares of the company’s stock valued at $39,022,000 after acquiring an additional 2,500,000 shares during the period. RA Capital Management L.P. bought a new position in Rezolute in the fourth quarter valued at about $21,665,000. Opaleye Management Inc. grew its holdings in shares of Rezolute by 595.9% during the 4th quarter. Opaleye Management Inc. now owns 6,287,156 shares of the company’s stock valued at $14,838,000 after purchasing an additional 5,383,714 shares during the last quarter. Balyasny Asset Management L.P. grew its stake in shares of Rezolute by 147.3% during the fourth quarter. Balyasny Asset Management L.P. now owns 4,506,861 shares of the company’s stock worth $10,636,000 after buying an additional 2,684,133 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Rezolute by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 4,410,082 shares of the company’s stock worth $41,455,000 after acquiring an additional 387,502 shares during the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.